Insilico Medicine vs Variational AI (2026)
Discovery teams use Insilico Medicine and Variational AI to generate small molecules for chemists to select, synthesize and test. Insilico offers Chemistry42 within a broad software and drug development business; Variational AI applies Enki through target focused collaborations. Chemistry42 generates molecular structures rather than screening only an existing library. It sits beside PandaOmics target identification, biologics design and other Pharma.AI modules, available through software licensing and collaborations. Insilico also develops its own medicines. Rentosertib has published discovery and Phase IIa results and entered Phase III, giving a concrete program history without proving that every licensed software project will reproduce that path. Enki designs against potency, unwanted activity and chemical property requirements, with further optimization able to preserve a chosen scaffold. Partners can use proprietary datasets to tailor the model. A Life Chemicals collaboration synthesized 19 selected candidates and found five with dual kinase activity; Rakovina advanced generated ATR inhibitors into further preclinical work. Those results remain specific to selected compounds and projects. Both require experimental validation, with commercial scope extending beyond the number of generated structures. Insilico fits research organizations wanting generative chemistry alongside target discovery tools or access to broader discovery partnerships. Variational AI fits partners framing a defined design problem around target properties and compound rights.
- Generative chemistry should sit beside target identification tools.
- The organization wants software licenses and collaboration options.
- A broader discovery platform is relevant to the program.
- Internal pipeline experience is useful context for a partnership.
- A collaboration centers on a defined target product profile.
- Optimization needs to preserve a chosen scaffold.
- Proprietary partner data should tailor molecule generation.
- Compound ownership and success milestones shape the agreement.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Insilico Medicine and Variational AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Insilico Medicine | Variational AI |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2014 | 2019 |
| Headquarters | Cambridge, Massachusetts | Vancouver, Canada |
| Website | insilico.com | variational.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Insilico Medicine is a generative AI drug discovery company (HKEX: 3696), headquartered in Cambridge, Massachusetts with operations in Hong Kong, Abu Dhabi and Shanghai, that both licenses software and develops its own medicines.
Source: AI Health Index, October 2026
Variational AI develops Enki, a generative model for designing small molecules against a research team's target product profile. Scientists specify desired potency, unwanted target activity and chemical properties. Enki proposes structures, and chemists select candidates for synthesis and laboratory testing.
Source: AI Health Index, October 2026
Questions buyers ask
How do Insilico Medicine and Variational AI work with the EHR?
Insilico describes a generic integration path: the suite runs on the client's preferred cloud (AWS, Azure or others as specified), a PandaOmics Box is offered for local deployment, and the company has published work on connecting its tools to other software through standard model context interfaces. The electronic lab notebook Insilico describes among its security controls is an internal system.
With Variational AI, output consists of candidate structures and properties that chemists use in subsequent synthesis and testing. The Merck agreement confirms use of partner data, and the product describes fitting into medicinal chemistry workflows. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
How are Insilico Medicine and Variational AI priced and sold?
Each product page routes to a request form, a PandaOmics Box is offered alongside the hosted products, and as a listed company Insilico reports its own financial results, which show its revenue rather than a customer's cost.
For Variational AI, the ImmVue agreement describes an initial fee and a payment tied to success, with exclusive ownership rights for the partner. Merck's two target collaboration also includes an upfront payment and milestones, potentially totaling $349 million. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
How do Insilico Medicine and Variational AI handle patient data?
With Insilico Medicine, the company's published privacy policy (effective October 30, 2020) covers the company website rather than the software.
In Variational AI's case, the general privacy policy limits personal information retention by purpose and legal need rather than a fixed deletion period. Compound uploads, model checkpoints and derived predictions have no complete lifecycle described. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
Which settings and specialties do Insilico Medicine and Variational AI cover?
For Insilico Medicine, results sit where the programs have run: a fibrosis candidate in Phase III, thirteen programs cleared for IND, and published work behind them.
With Variational AI, clinical care, patient selection and prescribing are outside the described workflow, while the broader target list represents available design coverage rather than demonstrated drug efficacy. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers.
Insilico Medicine is headquartered in Cambridge, Massachusetts, with international operations; Variational AI is based in Vancouver. Neither has a standard public rate card. Insilico's clinical pipeline evidence concerns specific programs, while Variational AI's current experimental examples remain preclinical.